The Number and Potency of Endothelial Progenitor Cells in  Type 2 Diabetes Mellitus Patients by Darmayanti, Siska et al.
Endothelial Progenitor Cells in T2DM Patients (Darmayanti S, et al.)Indones Biomed J. 2019; 11(2): 205-9DOI: 10.18585/inabj.v11i2.576
205
R E S E A R C H  A R T I C L E
The Number and Potency of Endothelial Progenitor Cells in 
Type 2 Diabetes Mellitus Patients 
Siska Darmayanti1,2,, Rini Hendriani1, Cynthia Retna Sartika3
1Magister Program of Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjajaran, Jl. Raya Bandung Sumedang Km 21, Jatinangor 45363, Indonesia
2Prodia Clinical Laboratory, Jl. Kramat Raya No.150, Jakarta 10430, Indonesia 
3Prodia Stem Cell Indonesia, Jl. Kramat VII No.11, Jakarta 10430, Indonesia
Corresponding author. E-mail: siska.darmayanti@prodia.co.id 
Received date: Oct 2, 2018; Revised date: May 6, 2019; Accepted date: May 13, 2019
BACKGROUND: Type 2 Diabetes Mellitus (T2DM) is a metabolic disease, due to the disorder of insulin function, insulin secretion, or both. Long-term 
hyperglycemia conditions promote endothelial dysfunction 
precedes to the development of multiple organ dysfunctions. 
Endothelial progenitor cells (EPCs) and hematopoietic 
stem cell (HSCs) are the key cellular effectors of postnatal 
neovascularization and play central role in endothelial 
dysfunction. However, in T2DM condition, the number 
of apoptotic HSCs increase, it may cause the reduction in 
potency and number of EPCs. In diabetes, the circulating 
EPCs number decrease and their functionality is impaired, 
but mechanism underlie of this impairement is unknown. 
The purpose of this study was to examine the relationship 
duration diabetes with  the number and potency of EPC cells 
in T2DM patients controlled and poorly controlled.
METHODS: Thirty-eight T2DM male patients were 
classified into two group based on Indonesian Society of 
Endocrinology/Perkumpulan Endokrinologi Indonesia 
(PERKENI) criteria   on T2DM.  The   first   group   was 
a controlled glycemic condition group (hemoglobin A1c 
(HbA1C) <7.0%) and the second group was a poorly 
controlled glycemic condition group (HbA1C >7.0%). 
Cluster of differentiation (CD)34+ and CD133+ expressions 
were used as specific marker for EPC, while quantified 
bright aldehyde dehydrogenase (ALDHbr) assay was used to 
represented the potency of EPCs. 
RESULTS: This study showed that in poorly controlled 
T2DM group the number of EPCs was lower by 24.80% 
(p<0.05) compared to the T2DM controlled group. Similarly, 
the expression of ALDHbr was lower by 43.07% (p<0.05) in 
poorly controlled group.
CONCLUSION:  There was a decrease in the number 
and potency of EPCs in poorly controlled T2DM patients 
compared to the controlled T2DM patients. There was also a 
strong negative correlation between the duration of diabetes 
and number of EPCs.
KEywORDS: ALDHbr, endothelial progenitor cells, type 
2 diabetes mellitus
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Abstract
Introduction
Type 2 Diabetes Mellitus (T2DM) is a metabolic disease, 
characterized by elevated levels of blood glucose, due to the 
impair insulin function, insulin secretion, or both. Usually in 
adults, it occurs when the body becomes resistant to insulin, 
or also known as insulin resistance. The prevalence of this 
disease has risen every year.(1) Long-term hyperglycemia 
conditions results in glucotoxicity by forming advanced 
glycosylation end products (AGEs), which contribute to 
the increased oxidative stress.(2) Long-term hyperglycemia 
also promotes endothelial dysfunction which precedes to 
the development of multiple organ dysfunctions. 
 Oxidative stress overwhelms the defense mechanisms 
of the vascular endothelium, which followed by an increase 
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of endothelial vasoconstriction, adhesion, inflammatory 
and pro-thrombotic molecules which results in endothelial 
damage. These conditions trigger body compensation to 
make improvements in maintaining vascular homeostatic 
and angiogenesis, by involving the proliferation and 
mobilization of immature cells for angiogenesis and 
covering the endothelial damage.(3)
 Circulating endothelial progenitor cells (EPCs) may 
play a major role in the capacity of vascular repair. Recent 
evidence, EPCs can proliferate, migrate and differentiate into 
endothelial cells to maintain the endothelial integrity and 
hemostasis.(4) In diabetes patients, hyperglycemia increases 
reactive oxygen species (ROS) and AGEs production which 
may impair the EPC function. EPC number and function 
have been shown to be significantly diminished in diabetic 
patients compared to healthy controls. The mechanism 
underlying this decrease in number and functionality 
impairment are still poorly understood.(5) 
 Experimental studies have shown that high glucose 
concentrations exposure EPC to increase superoxide 
anions and reduce bioavailability of nitric oxide (NO). EPC 
dysfunction, which may be involved in the pathogenesis of 
vascular complications due to endothelial insufficiency in 
the process of vascular generation.(6,7) Physiologically, 
EPC has a role in revascularization through the enzyme 
aldehyde dehydrogenase (ALDH), an enzyme that catalyzes 
the pyridine nucleotide associated with aldehyde oxidation, 
into carboxylic acid, which converts acetaldehyde to acetyl 
acid, as energy so that cells can carry out cell functions in 
development, increase and revascularization. ALDH beam 
measurements are the measurements of light. For example 
is bright ALDH (ALDHbr) expresseion in cells describes 
the cell's potential and representatively predict the cell's 
capacity to proliferate and engraftment.(8)
 The aim of this study was to determine the number 
of circulating EPC and potency of EPCs in controlled and 
poorly controlled T2DM patients, thereby providing an 
additional information regarding the relationship of EPC 
with vascular complications in T2DM.
Methods
Subjects
This was an observational cross-sectional study held in 
Jakarta during December 2017. The ethical approval 
was obtained from The Ethics Commission of Faculty of 
Medicine, Universitas Padjadjaran (No. 1027/UN6.C.10/
PN/2017). Thirty-eight male T2DM male subjects with 
T2DM were enrolled in this study. All subjects had given 
written informed consent before participating.
 Subjects’ clinical history, medications, and their 
glycosylated hemoglobin (HbA1C) results were reviewed. 
Controlled and poorly controlled patients were grouped 
based on the T2DM criteria determined by Indonesian 
Society of Endocrinology/Perkumpulan Endokrinologi 
Indonesia (PERKENI) in 2015.  Subjects with HbA1C 
<7.0% were grouped into controlled glycemic condition 
group and  subjects with HbA1C >7.0% were group into 
poorly controlled glycemic condition group. There was no 
subjects with coronary artery disease and hypertension. 
HbA1c Test
The venous blood samples were collected and the 
examined to find the concentration of HbA1c by using 
high performance liquid chromatograph (HPL-C)-ion 
exchange method (Variant, Biorad, California, USA). The 
concentration was expressed in units of percent (%).
Quantification of EPC Numbers and Cell Potential
To analyze the number and potency of EPCs, the cell sorting 
process was carried out using the flow cytometry method 
(BD FACSCANTO II, Bioscience, California, USA). The 
number of EPCs was identified with surfaces markers 
with staining, by counting the expression of cluster of 
differentiation (CD)34+ (CD34 Antibody, Miltenyi Biotec, 
Bologna, Italy) and CD133+ (CD133 Antibody, Miltenyi 
Biotec) antigen surfaces.
 The evaluation of potency EPCs  was  done  using the 
ALDEFLOUR kit (Catalogue #01700, Stemcell Technology, 
Vancouver, Canada). One mL ALDEFLUOR assay buffer, 
5 µL ALDEFLUOR DEAB, and 5 µL ALDEFLUOR was 
added to the sample (cell suspension). Sample was incubated 
for 45 minutes and centrifuged for 5 minutes. Then the 
supernatant was discarded and the pellet was added with 
0.1 mL ALDEFLUOR buffer assay and transferred to the 
trucount tube. The cocktail mixed antibodies were added to 
the sample, followed by 20 minutes incubation at 4°C.
Statistical Analysis
The data were analyzed using SPSS 24 software (SPSS 
Inc., Chicago, USA) for Windows operating systems. The 
standard error used was 5%. The data obtained were tested 
with the Shapiro-Wilk method to determine the distribution 
pattern. It was further tested with Spearman correlation test 
and Mann-Whitney U-test.
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Results
From the results of this study, we obtained an abnormal 
distribution pattern. The age range of subjects who 
participated in this study was 31-68 years old, meanwhile the 
duration since they were diagnosed with T2DM was varied 
from 1-27 years. There were 8 subjects classified as the 
controlled T2DM patients and 30 subjects classified as the 
poorly controlled. The subjects’ characteristic comparison 
between the controlled and poorly controlled T2DM group 
were presented in Table 1. 
 From the characteristics of the subjects, there was no 
significant  difference  in age  and  duration  of  diabetes 
between  the  two  groups  of  T2DM  patients.  It  illustrated 
that  the  age and  duration  of  diabetes  do  not  distinguish 
the T2DM group from being controlled or poorly controlled. 
In the poorly controlled T2DM group, the number of 
circulating EPC was lower compared to the controlled 
Median Percentile 5 Percentile 95 Median Percentile 5 Percentile 95
Age (years) 52 32 63 55 34 65 0.52
Duration of diabetes (years) 3 1 23 4 1 16 0.58
HbA1c (%) 6.7 5.8 6.9 9.6 7 14.7 0.00*
EPC (cell/mL) 60.75 6.88 798.4 13.43 0 156.83 0.04*
EPC + ALDHbr 60.75 6.88 249.5 13.43 0 153.26 0.03*
Controlled (n=8) Poorly Controlled (n=30)
p  value
Table 1. Study subjects characteristics.




















Figure 1. Number of circulating EPC 
in the controlled group and poorly 
controlled group. 
group (Figure 1). The median number of circulating EPC 
in controlled group was significantly higher than the poorly 
controlled group (60.75 vs. 13.43, p=0.04).
  The EPCs number carried out in  the study showed 
a difference between poorly controlled and controlled 
groups, where the number of circulating EPC in the 
significantly poorly controlled group decreased compared 
to the controlled group, as also presented in Figure 2. The 
numbers of circulating EPCs, was determined by the co-
expression of CD34+ and CD133+, with the area of getting 
low side scatter vs. forward scatter (SSC/FSC), which was 
quantified by using flow cytometry.
 Furthermore,  ALDHbr  expression  in  the  cells  were 
also  shown  in  getting  low  scatter  slides  (Figure  3).  In 
T2DM  patients,  the  number  of  EPC  that  given  ALDHbr 
was significantly lowered in poorly controlled group 
compared to the controlled group (p<0.05). Based on the 
Spearman’s correlation analysis, the number of circulating 
EPC  were  positively  correlated  with  the  number  of 
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Figure 2.  EPC numbers were determined by flow cytometry for the co-expression of CD34+ and CD133+. 
Figure 3. Getting area of EPC that express ALDHbr.
Discussion
It was found that EPC number was higher in the controlled 
group compared to the poorly controlled group. The 
results of this study are in line with a study conducted in 
2010, which showed a significantly lower number of EPC 
(CD34+ EPC) between poorly controlled T2DM compared 
to healthy group, which was 0.767±0.18 and 1.033±0.27, 
with p=0.203.(7) Uncontrolled long-term hyperglycemia 
conditions contribute to an increased oxidative stress and 
AGE which results in a decrease in the number of circulating 
EPC.(2) Furthermore, uncontrolled ROS conditions are a 
significant trigger in  the stem/progenitor cell-related aging, 
which can lead to an inactivation of telomerase.(9-11) 
 The positive correlation between EPC and EPC + 
ALDHbr in this study illustrates that high ALDH activity 
elevated with increasing number of EPC. Significant 
differences of EPC added by ALDH between controlled and 
poorly controlled groups is that the expression of ALDH is 
higher in low ROS conditions.(12,13) ALDH is a family  of 
19 cytosolic enzymes that can catalyze pyridine which  is 
associated with the oxidation of aldehydes to carboxylic 
acids.(9) ALDH plays a role in the oxidation process of 
intracellular aldehydes and oxidation of retinol into retinoic 
acid during the early stages of stem cell development 
which has pro/anti-angiogenic effects  for endothelial cell 
cytokine modulation, migration and vasculogenesis effects.
(14) ALDH shows the potency of progenitor cells, which 
are related to its function and colonization. A previous 
study suggested that ALDHbr cells are predictive of 
engraftment, which would be expected because this enzyme 
is characteristically highly expressed in the hematopoietic 
stem and progenitor cells from human umbilical cord blood, 
bone marrow, and mobilized peripheral blood.(8) 
 Interestingly, in this study, there was no correlation 
between HbA1c and the number of EPC, but there was a 
strong negative correlation between the duration of diabetes 
and a decrease in the number of EPC. This result is consistent 
with the another study conducted in 2015 which reported 
an insignificant association between circulating CD34+ cell 
counts and HbA1c levels in T2DM patients.(15) Likewise, 
it was stated that in patients with duration of diabetes >10 
years, CD34+ cell counts were lower than patients with 
duration of diabetes <10 years.(3) 
 Results of this study shows that the exposure to 
hyperglycemia contributes to reducing the number and 
potential of EPC cells. The lower number of EPC in the 
peripheral blood circulation in the poorly controlled group 
is related to impaired mobilization from hematopoietic stem 
cell (HSC) and EPC, reflecting a disturbed niche function 
due to diabetes conditions.(16) Mobilization disorders begin 
with increased oxidative stress condition, pro-inflammatory 
EPC that given ALDHbr (r=0.99, p<0.05), as well inversely 
associated with the duration of diabetes (r=-0.37, p<0.05). 
The activity of ALDHbr in EPCs was around 55.5% and 96% 
for controlled  and  poorly  controlled  group, respectively.
 There was no correlation between HbA1c and the 
number of EPC, but there was a strong negative correlation 
(r=-0,347, p=0.03) between the duration of diabetes and 
the number of EPC, as well as the duration of diabetes and 
number of EPC + ALDHbr (r=-0.367*, p=002).
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Conclusion
There was a decrease in the number and potency of EPC in 
poorly controlled T2DM patients compared to the controlled 
T2DM patients and also a strong negative correlation 
between the duration of diabetes and number of EPC. 
Further studies of EPC and EPC with ALDHbr as a marker 
to detect cardiovascular disease risk in diabetics is needed. 
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factors and apoptosis which cause vascular complications. 
(3) The  high ROS accumulation can causes stem cell-related 
aging which lead to HSC and EPC mobilization.(10,17,18). 
A decrease in the number of progenitor cells from the 
spinal cord is characterized by a lower number of cells in 
circulation. This is caused by disruption of progenitor cell 
mobilization and increased apoptosis associated with long-
term diabetes exposure.(3)
